| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 1.07 [0.86, 1.33] | | < 1 | | 0% | 1 study (1/-) | 27.2 % | NA | not evaluable | | crucial | - |
| progression or deaths (PFS) | 1.17 [0.95, 1.44] | | < 1 | | 0% | 1 study (1/-) | 6.6 % | NA | not evaluable | | important | - |
| objective responses (ORR) | 0.70 [0.46, 1.06] | | > 1 | | 0% | 1 study (1/-) | 4.7 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| STRAE (any grade) | 0.93 [0.60, 1.46] | | < 1 | | 0% | 1 study (1/-) | 62.1 % | NA | not evaluable | | non important | - |
| STRAE (grade 3-4) | 0.82 [0.50, 1.33] | | < 1 | | 0% | 1 study (1/-) | 79.2 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.20 [0.12, 0.34] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 0.21 [0.14, 0.31] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (any grade) | 0.70 [0.41, 1.20] | | < 1 | | 0% | 1 study (1/-) | 90.0 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 1.24 [0.64, 2.40] | | < 1 | | 0% | 1 study (1/-) | 26.6 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Alopecia TRAE (grade 3-4) | 0.98 [0.02, 49.83] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 0.02 [0.00, 0.13] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 0.12 [0.01, 2.31] | | < 1 | | 0% | 1 study (1/-) | 91.7 % | NA | not evaluable | | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 1.97 [0.07, 59.09] | | < 1 | | 0% | 1 study (1/-) | 35.0 % | NA | not evaluable | | non important | - |
| Constipation TRAE (grade 3-4) | 0.98 [0.02, 49.83] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.24 [0.03, 2.19] | | < 1 | | 0% | 1 study (1/-) | 89.5 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.59 [0.14, 2.48] | | < 1 | | 0% | 1 study (1/-) | 76.5 % | NA | not evaluable | | non important | - |
| Dysgeusia TRAE (grade 3-4) | 0.98 [0.02, 49.83] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.20 [0.06, 0.71] | | < 1 | | 0% | 1 study (1/-) | 99.4 % | NA | not evaluable | | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 1.19 [0.36, 3.94] | | < 1 | | 0% | 1 study (1/-) | 39.0 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.98 [0.02, 49.83] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 3.51 [0.72, 17.07] | | < 1 | | 0% | 1 study (1/-) | 6.0 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.05 [0.00, 0.92] | | < 1 | | 0% | 1 study (1/-) | 97.7 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.97 [0.07, 59.09] | | < 1 | | 0% | 1 study (1/-) | 35.0 % | NA | not evaluable | | non important | - |
| Mucosal inflammation TRAE (grade 3-4) | 0.98 [0.02, 49.83] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.19 [0.02, 1.67] | | < 1 | | 0% | 1 study (1/-) | 93.1 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.02 [0.00, 0.25] | | < 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 0.98 [0.02, 49.83] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 0.98 [0.02, 49.83] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 0.49 [0.02, 14.72] | | < 1 | | 0% | 1 study (1/-) | 65.7 % | NA | not evaluable | | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.49 [0.02, 14.72] | | < 1 | | 0% | 1 study (1/-) | 65.7 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 1.98 [0.18, 21.94] | | < 1 | | 0% | 1 study (1/-) | 29.1 % | NA | not evaluable | | non important | - |
| Renal and urinary disorders TRAE (grade 3-4) | 1.97 [0.07, 59.09] | | < 1 | | 0% | 1 study (1/-) | 35.0 % | NA | not evaluable | | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 12.07 [0.67, 217.19] | | < 1 | | 0% | 1 study (1/-) | 4.7 % | NA | not evaluable | | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 5.00 [0.58, 43.09] | | < 1 | | 0% | 1 study (1/-) | 7.3 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.49 [0.02, 14.72] | | < 1 | | 0% | 1 study (1/-) | 65.7 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.04 [0.01, 0.31] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.10 [0.01, 1.78] | | < 1 | | 0% | 1 study (1/-) | 94.0 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| Increase AST AE (grade 3-4) | 7.05 [0.86, 57.74] | | < 1 | | 0% | 1 study (1/-) | 3.5 % | NA | not evaluable | | non important | - |
